Eterna Therapeutics Inc (ERNA)

$0.23 -0.02 (-6.24%)
Market Cap 1.43M
Revenue (ttm) 580,000.00
Net Income (ttm) -44.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,679.31%
Debt to Equity Ratio 0.00
Volume 359,085
Avg Vol 12,707,749
Day's Range N/A - N/A
Shares Out 5.41M
Stochastic %K 48%
Beta 4.47
Analysts Hold
Price Target N/A

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 582 1199
Address:
1035 Cambridge Street, Suite 18A, Cambridge, United States
Khamas
Khamas Oct. 15 at 8:53 PM
$ERNA ready to make a move
0 · Reply
StockChiefs
StockChiefs Oct. 12 at 5:49 PM
MTEX has only 600k shares outstanding and started to make its move up Friday! Don't miss MTEX . I would rather buy before they run 200% up.. 💎 Spiked towards $15 recently . Looks like once people find MTEX we could see a squeeze up again! $LUCY $WETH.X $ERNA $ARTL will run soon
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 10:42 PM
Keep a close watch on CMCT! ITS MOVING!! $AMZE $SST $ERNA $EMPD .
0 · Reply
Russell25
Russell25 Oct. 6 at 10:37 PM
$SPRB rooting for $ERNA
0 · Reply
Khamas
Khamas Oct. 6 at 7:59 PM
$ERNA
0 · Reply
Trtrucking79
Trtrucking79 Oct. 4 at 4:00 PM
$ERNA loaded a few shares of this…
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 3 at 12:35 AM
$ARTL $AMZE $SST $ERNA )
0 · Reply
Russell007xx
Russell007xx Sep. 26 at 5:28 PM
$ERNA a complete trash stock , under 1 soon
0 · Reply
ka1954
ka1954 Sep. 25 at 2:42 PM
$ERNA if some of u fuckers stop selling, then we could have a chance to stop going down !!!
0 · Reply
Russell007xx
Russell007xx Sep. 25 at 10:43 AM
$ERNA a scam stock
0 · Reply
Latest News on ERNA
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Oct 1, 2025, 8:30 AM EDT - 24 days ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 29, 2025, 8:30 AM EDT - 26 days ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 17, 2025, 8:30 AM EDT - 5 weeks ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 10, 2025, 8:30 AM EDT - 6 weeks ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:30 AM EDT - 7 weeks ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jul 9, 2025, 8:30 AM EDT - 3 months ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 25, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 24, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Jun 10, 2025, 9:30 AM EDT - 4 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 28, 2025, 8:30 AM EDT - 5 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 14, 2025, 8:30 AM EDT - 5 months ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 29, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Ernexa Therapeutics Closes New Funding Round

Apr 3, 2025, 8:55 AM EDT - 7 months ago

Ernexa Therapeutics Closes New Funding Round

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Feb 26, 2025, 8:30 AM EST - 8 months ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 14, 2025, 8:30 AM EST - 10 months ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Jan 9, 2025, 7:30 AM EST - 10 months ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 10, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

May 8, 2024, 9:31 AM EDT - 1 year ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Feb 20, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Jan 3, 2024, 4:15 PM EST - 1 year ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Dec 14, 2023, 6:56 PM EST - 2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 24, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 17, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

May 2, 2023, 7:30 AM EDT - 2 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Mar 20, 2023, 4:10 PM EDT - 2 years ago

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Feb 22, 2023, 8:00 AM EST - 2 years ago

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

Jan 4, 2023, 8:30 AM EST - 3 years ago

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics

Dec 20, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

Nov 1, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

Oct 18, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

Oct 17, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

Khamas
Khamas Oct. 15 at 8:53 PM
$ERNA ready to make a move
0 · Reply
StockChiefs
StockChiefs Oct. 12 at 5:49 PM
MTEX has only 600k shares outstanding and started to make its move up Friday! Don't miss MTEX . I would rather buy before they run 200% up.. 💎 Spiked towards $15 recently . Looks like once people find MTEX we could see a squeeze up again! $LUCY $WETH.X $ERNA $ARTL will run soon
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 10:42 PM
Keep a close watch on CMCT! ITS MOVING!! $AMZE $SST $ERNA $EMPD .
0 · Reply
Russell25
Russell25 Oct. 6 at 10:37 PM
$SPRB rooting for $ERNA
0 · Reply
Khamas
Khamas Oct. 6 at 7:59 PM
$ERNA
0 · Reply
Trtrucking79
Trtrucking79 Oct. 4 at 4:00 PM
$ERNA loaded a few shares of this…
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 3 at 12:35 AM
$ARTL $AMZE $SST $ERNA )
0 · Reply
Russell007xx
Russell007xx Sep. 26 at 5:28 PM
$ERNA a complete trash stock , under 1 soon
0 · Reply
ka1954
ka1954 Sep. 25 at 2:42 PM
$ERNA if some of u fuckers stop selling, then we could have a chance to stop going down !!!
0 · Reply
Russell007xx
Russell007xx Sep. 25 at 10:43 AM
$ERNA a scam stock
0 · Reply
Johnnytwofour2
Johnnytwofour2 Sep. 24 at 8:59 PM
$ERNA What a complete disregard for shareholders. I'm insulted by the why this company has kept us in the dark. Divested today. Not worth the risk at all. Their website is something a child put together. Its actually terrible. You can have this steaming pile bears.
0 · Reply
ka1954
ka1954 Sep. 24 at 8:19 PM
$ERNA piece of crap
0 · Reply
Chickendinner1
Chickendinner1 Sep. 22 at 11:50 PM
$ERNA under 1 soon
0 · Reply
Chickendinner1
Chickendinner1 Sep. 22 at 10:06 PM
$ERNA they are presenting the same data for 9 months already. Scam
0 · Reply
Zorrelak
Zorrelak Sep. 22 at 3:24 PM
$ERNA bizarre- data presented over the weekend yet shareholders are in the dark
0 · Reply
Chickendinner1
Chickendinner1 Sep. 22 at 12:32 PM
$ERNA scam. Every time says they will announce data but no news at all. Scammers
0 · Reply
QY1988
QY1988 Sep. 22 at 12:20 AM
$ERNA Where are the data news? I'm hope the news will drive the price up to the new level🚀🚀🚀😂
0 · Reply
ru8fru
ru8fru Sep. 19 at 5:39 PM
$ERNA data Saturday holding over the weekend.
0 · Reply
Khamas
Khamas Sep. 19 at 2:08 PM
$ERNA
0 · Reply
Johnnytwofour2
Johnnytwofour2 Sep. 19 at 11:48 AM
$ERNA Potentially some support at $1.27 based on the lvl 2:
0 · Reply
Wakaas93
Wakaas93 Sep. 17 at 11:27 PM
$ERNA Should see a run up into results on Saturday $2 target
0 · Reply
Russell007xx
Russell007xx Sep. 17 at 11:16 PM
$ERNA looks like under tomorrow under 1
0 · Reply